Salanersen’s Phase 1b: a clear biomarker and motor signal in post–gene‑therapy SMA—Phase 3 will test whether it changes care
Biogen’s Phase 1b results for salanersen showed a pronounced drop in a neurodegeneration biomarker and measurable motor gains in children…